Testing a digital remote monitoring tool for patients with melanoma on immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study tests whether a digital remote patient monitoring tool, paired with a wearable device, is feasible and acceptable for people receiving immune checkpoint inhibitors for melanoma. Participants will complete baseline, midpoint, and end-of-study questionnaires, with an optional in-person physical function test. If randomized to the intervention, they will provide weekly symptom ratings and wear a Fitbit for about 90 days, with data linked to study IDs. The trial aims to determine whether the digital monitoring improves symptom management, quality of life, and engagement with the care team compared with usual care. Recruitment targets 40 participants from UPMC Hillman Cancer Center and will collect demographic, clinical, and health utilization data to contextualize findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* receiving immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center for melanoma;
* age 18 years or older;
* ability to read and write in English;
* owns and uses a smartphone capable of running study applications

Exclusion Criteria:

* under 18 years old; and
* unable to read and write in English

Where it's running

• UPMC Hillman Cancer Center
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Carissa A Low — University of Pittsburgh
• Study coordinator: Carissa A Low
• Email: lowca@upmc.edu
• Phone: 412-623-5973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.